Pharmaceutical Composition Containing Mitochondria-Targeting Compound for Treating Macular Degeneration

Thu, 09 Apr 2026 12:25:57 +0000
Intellectual Property

The USPTO published patent application US20260097092A1 filed by Ulsan National Institute of Science and Technology for a pharmaceutical composition containing mitochondria-targeting compounds as active ingredients for treating macular degeneration and other retinal diseases. The application specifically covers compounds that induce apoptosis of senescent cells for prevention and treatment of aging-related diseases. The application was originally filed on January 11, 2023.